Skip to content
MarketScale
‹ Back to IndustriesSciences

How Science and Technology is Revolutionizing the Cannabis Industry

Cannabis development is highly attributed to plant breeding and targeted cultivation strategies. Crops themselves are entirely different from those in the 1970s, and we’ve learned a lot by fine-tuning our techniques. According to Anders Peterson, Cannabis Operations Specialist at InSpire Transpiration Solutions, science and technology have been game-changing for cannabis development. “We’ve been able to…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Cannabis
Share

Key takeaways

01

Cannabis development is highly attributed to plant breeding and targeted cultivation strategies.

02

Crops themselves are entirely different from those in the 1970s, and we’ve learned a lot by fine-tuning our techniques.

03

According to Anders Peterson, Cannabis Operations Specialist at InSpire Transpiration Solutions, science and technology have been game-changing for cannabis development.

Cannabis development is highly attributed to plant breeding and targeted cultivation strategies. Crops themselves are entirely different from those in the 1970s, and we’ve learned a lot by fine-tuning our techniques.

According to Anders Peterson, Cannabis Operations Specialist at InSpire Transpiration Solutions, science and technology have been game-changing for cannabis development.

“We’ve been able to collect a significant more amount of data and learn from it, even just over the past five years,” said Peterson. “Besides that, the technology used to create a controlled environment inside in terms of lighting, fertigation, HVAC, have allowed us to also optimize plant growth and production and efficiency in these spaces.

In the same ways that farmers learn over time what crops grow best in what areas, we learn to isolate environmental factors to optimize plant growth. Starting with data collection, we better understand what the plants need.

These developments have decreased the number of days plants take to reach maturity and, in turn, increased the number of harvests a year within greenhouses. Specifically, within InSprire Transpiration Solutions, technology has increased harvest cycles from four per year to six. Similar techniques are developing in outdoor cannabis development and production.

In addition to environmental developments, we have also seen cannabis development in the plants themselves through crop steering and breeding. In the 1970s, THC levels in cannabis plants consistently registered 8-12%. Nowadays, plants are testing in the range of 35 to 40% with some cultivars. That’s a significant increase. A lot of that is down to the changes in plant breeding. However, targeted cultivation strategies also contribute to that shift.

Video TranscriptExpand ↓

Hi, my name is Anders Peterson with InSpire Transpiration Solutions. I'm an indoor cannabis cultivator for the past 12 years and a cell molecular biologist. And today, the question is how was an increased understanding of technology and science changing the cannabis industry? Well, a better understanding of science and technology has changed the cannabis industry in a number of ways. And specifically, when it comes to cultivation, it has allowed us to optimize plant performance, including yield and secondary metabolite concentration like cannabinoids and terpenes. And it's allowed us to optimize the production of the plant, primarily in an indoor setting, but also in the field. And in greenhouses. An example of this in an indoor scenario is that with data collection, a better understanding of the levers to pull for cultivation in terms of the Cardinal parameters of plant growth, we've been able to shorten cycle times and basically speed up plant growth so that we're getting additional harvests per year which is just increasing the bottom line for many of these cannabis cultivation businesses. For example, a while ago, an indoor flowering room would only get four harvest a year. Now we're shooting for getting six. So that's a significant more amount of product coming out of each space per year. All due to better understanding of science and technology. The advent of cheaper sensor technology and kind of the IOT of things has allowed us to learn a lot of these things that have, uh, you know, a lot of the parameters to optimize, because sensors have gotten so much cheaper more widely accessible. We've been able to collect a significant more amount of data and learn from it, even just over the past five years. Besides that, the technology used to create a controlled environment inside in terms of lighting, fertigation, HVAC, have allowed us to also optimize plant growth and production and efficiency in these spaces. So, really it's kind of changed the game, increasing, you know, a better understanding of technology and science. I'm looking forward to some really interesting research that's going to be coming out in the next year or so, that will even further optimize these indoor controlled environments, allowing us to reach new levels of plant performance in the cannabis crop that we've never seen before. I mean, just as a benchmark of back in the seventies, most cannabis dried flower tested in the THC percentages around eight to 12%. Nowadays, we're testing in the range of 35 to 40% with some cultivars. That's a significant increase. A lot of that is done through breeding, but also much more targeted cultivation strategy. That's allowed us to use techniques like crop steering, both in the irrigation side and in the environment that allow us to push the plant in certain predicted outcomes that are beneficial for the cultivator and for the crop. So it's really been quite amazing.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512